drugset / Trial / NCT06015152

Comparison Of Efficacy Of Tazarotene 0.045% Vs Halobetasol Propionate 0.01% Lotion For Treatment of Scalp Psoriasis

NCT06015152

Completed 90 enrolled Jinnah Postgraduate Medical Centre
RandomizedParallel-groupOpen-labelTreatment

Summary

Psoriasis is a serious, immune-driven illness that affects around 2% of the population and has a wide range of clinical manifestations 1-3 . Many patients have localized illness, and topical therapy can be an important part of treatment. tazarotene is the first receptor-selective retinoid for the topical treatment of plaque psoriasis. On application, tazarotene is rapidly hydrolyzed to its main metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs) in the nucleus. Tazarotenic acid selectively binds to RARs b and g . The predominant type of RAR expressed in the human epidermis is RAR, indicating that it may be an important mediator of retinoid action in skin. .

Timeline

Start
2022-08-01
Primary completion
2022-12-01
Completion
2023-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tazarotene Small molecule 0.045 % Topical

Indications